BioCardia Inc
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
BCDA$0.90+6.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. EXHIBIT INDEX
| Exhibit Number | Exhibit Description |
| 3.1(1) | Amended and Restated Certificate of Incorporation, as amended May 6, 2019 |
| 3.2(2) | Amended and Restated Bylaws |
| 4.1(3) | Form of Securities Purchase and Registration Rights Agreement, dated February 9, 2024, by and among the Company and the investors named therein |
| 31.1* | Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2* | Certification of Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1** | Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 32.2** | Certification of Principal Financial Officer Pursuant to Rule 13a-14(b) and Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101.INS+ | Inline XBRL Instance Document |
| 101.SCH+ | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL+ | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF+ | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB+ | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE+ | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101) |
| * | Filed herewith. |
| ** | Furnished herewith. |
| (1) | Previously filed as Exhibit 3.1 to the Form 10-Q for the quarterly period ended June 30, 2019 filed by us on August 14, 2019. |
| (2) | Previously filed as Exhibit 3.2 to the Current Report on Form 8-K filed by us on May 1, 2023. |
| (3) | Previously filed as Exhibit 4.1 to the Current Report on Form 8-K filed by us on February 9, 2024. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| BIOCARDIA, INC. (Registrant) | ||
| Date: May 14, 2024 | By: | /s/ Peter Altman |
|---|---|---|
| Peter Altman | ||
| President and Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| Date: May 14, 2024 | By: | /s/ David McClung |
| David McClung | ||
| Chief Financial Officer | ||
| (Principal Financial and Accounting Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.